Financial Tearsheet

Company Overview

NuGenerex Immuno-Oncology, Inc. is a clinical stage biotechnology company focused on harnessing the power of the innate immune system to treat cancer and infectious disease with a pipeline of immunotherapy indications based on our proprietary, patented platform technology, Ii-Key.

The Company’s lead immunotherapy product candidate is AE37, an Ii-Key-HER2 peptide vaccine for breast, prostate, and bladder cancer which incorporates our li-peptide linker to a designated antigen that activates the immune system targeting specific cancer cells. Ex-Vivo human studies are currently underway for our COVID Ii-Key Complete Vaccine and clinical trials are expected to begin in early 2021.

IR Contacts

Investor Relations Transfer Agent

Todd Falls
1-800-391-6755 Ext. 222
investor@nugenerexio.com

Securities Transfer Corporation (STC)
2901 N Dallas Parkway
Suite 380
Plano, Texas 75093
(469) 633-0101

Legal Counsel Auditor

Jeffrey P. Wofford, Esq.
Carmel, Milazzo & Feil LLP
55 West 39th Street, 18th Floor
New York, New York 10018

Mazars, LLP
215 St Jacques St.
Montreal, QC H2Y 1M6
Canada

Recent XBRL Filings

Filing Date Form Type Description View
Oct 29, 2020 10-K Annual report htmlhtml   pdfpdf   xbrlxbrl  
Jun 19, 2020 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
Jun 17, 2020 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  

Management Team

Joseph Moscato, Chairman, Chief Executive Officer, President

Richard Purcell, Director, Executive Vice President of Research & Development

Mark Corrao, Chief Financial Officer

Eric von Hofe, Ph.D., Chief Scientific Officer

Dr. Jason B. Terrell, MD., Chief Medical Officer

Anthony S. Crisci, Esq., C.P.A., Chief Legal Officer

Board of Directors

Joseph Moscato, Chairman, Chief Executive Officer, President

Anthony S. Crisci, Esq., C.P.A., Chief Legal Officer

Richard Purcell, Director, Executive Vice President of Research & Development

Dr. Craig Eagle, MD, Vice President of Medical Affairs Oncology for Genentech

S. Gail Eckhardt, MD, Tenured Professor at the University of Texas at Austin’s Dell Medical School

Dr. Marvin S. Hausman, MD, Immunologist and Board-Certified Urological Surgeon

Thomas Leonard, MPA, Pharmaceutical Sales, Marketing, and Management at Bristol Myers Squibb

Brian T. McGee, Chairman of the Generex Audit Committee | Member of the Generex Compensation and Corporate Governance and Nominating Committees

Dr. Carol Nacy, PhD, Founder and the Chief Executive Officer of Sequella, Inc.